Table 6.

Association of Clinical and Non-Clinical Factors to Chemotherapy in Men with Invasive Breast Cancer and to Tamoxifen or Aromatase Inhibitors in Men with Estrogen Receptor Positive Invasive Tumors

		Invasive tumors Chemotherapy				ER positive/borderline tumors Tamoxifen or Aromatase Inhibitor
			95% CI				95% CI
	p-value	OR	LL	UL	p-value	OR	LL	UL
Tumor Size	<0.01				0.74
<2 cm		1.0				1.0
2-<5cm		2.5	1.5	4.3		0.9	0.6	1.5
5+ cm		1.7	0.6	5.3		1.3	0.4	3.9
Nodal status	<0.0001				0.22
Positive nodes		1.0				1.0
Negative/other		0.2	0.1	0.3		0.7	0.4	1.2
Estrogen Receptor status	0.06
Positive/borderline		1.0
Negative/other		0.5	0.2	1.0
Charlson Score	0.73				0.65
Zero		1.0				1.0
1+		0.9	0.5	1.6		0.9	0.5	1.5
Age	<0.0001				0.05
<50		1.0				1.0
50-59		1.1	0.4	2.8		2.9	1.2	7
60-69		0.8	0.3	1.9		2.3	1.03	5.4
70-79		0.3	0.1	0.8		2.3	0.95	5.5
80+		0.03	0.01	0.1		1.2	0.5	3
Race/ethnicity	0.78				0.23
Non-Hispanic White		1.0				1.0
Non-Hispanic Black		0.8	0.4	1.7		0.8	0.4	1.6
Other		0.8	0.4	1.9		1.8	0.8	3.9
Marital Status	<0.01				0.79
Married		1.0				1
Not married		0.4	0.2	0.8		1.1	0.6	1.8
Insurance	0.07				0.24
Private		1.0				1.0
Any Medicaid		1.5	0.6	3.9		0.5	0.2	1.4
Medicare only		2.6	1.2	5.8		1.1	0.5	2.2
No insurance/Unknown		0.6	0.2	2.1		0.4	0.1	1.2
Residency training	0.08				0.07
No/unknown		1.0				1.0
Yes		0.6	0.4	1.1		1.6	0.96	2.6
Hospital bed size	0.46				0.3
<200, OPD		1.0				1.0
200-299		1.0	0.5	2.0		0.8	0.4	1.6
300-399		0.8	0.4	1.7		0.9	0.4	1.9
400-499		1.6	0.7	3.7		1.9	0.9	4.0
500+		0.8	0.4	1.9		1.3	0.6	2.7